Dual checkpoint blockade of CD47 and PD-L1 using a novel affinity-tuned bispecific antibody maximizes anti-tumor immunity (scRNA-Seq)

A novel affinity-tuned dual-checkpoint bispecific antibody with potent PD-L1 and moderate CD47 affinity was designed to improve the selectivity to TME and thus enhance antitumor immunity and efficacy. The scRNAseq analysis was performed to examine the immune cell modulation in TME following the CD47/PD-L1 bispecific treatment. Overall design: MC38 tumor-bearing C57/BL6 mice were treated with vehicle control, aCD47, aPD-L1 monotherapy, their combination, or the bispecific antibody every 3 to 4 days starting at day 10 post-tumor implant. Tumors were harvested at day 20 and preared for scRNAseq analysis (n = 4~5 mice/group).